Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

ESMO Colloquium supported by Apogenix - Recurrent glioblastoma management: Challenges and opportunities

CD95L/Fas ligand selective inhibition: Rationale and clinical results

Date

30 Sep 2019

Session

ESMO Colloquium supported by Apogenix - Recurrent glioblastoma management: Challenges and opportunities

Topics

Cytotoxic Therapy

Tumour Site

Central Nervous System Malignancies

Presenters

Wolfgang Wick

Authors

W. Wick

Author affiliations

  • University of Heidelberg, 69120 - Heidelberg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Biology of CD95/Fas/CD95L

Presenter: Michael Weller

Session: ESMO Colloquium supported by Apogenix - Recurrent glioblastoma management: Challenges and opportunities

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.